ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, in one study, CML recurred in more than 50% of patients who discontinued imatinib therapy after having achieved and maintained at least a 5-log reduction in BCR-ABL mRNA transcript levels, or a complete molecular response [8].